How many people are taking GLP-1 agonists
As of the most recent large surveys and health system data, several million adults in the United States are taking GLP-1 receptor agonists for type 2 diabetes and, increasingly, for weight management. Estimates from national health interviews and commercial claims data suggest that current use has grown rapidly over the past several years, with the highest adoption among adults with higher incomes and better insurance coverage. Below, this overview explains who is using these medications, how prevalence and trends differ by region and payer, and what factors limit a precise global headcount.
Prescription claims and survey estimates in the United States
National health survey data
U.S. national estimates from large household surveys and pharmacy claims analyses show that hundreds of thousands to low millions use GLP-1 agonists, with recent growth driven by newer agents such as semaglutide and tirzepatide. Key sources include:
- National Health and Nutrition Examination Survey (NHANES) prescription self-reports and pharmacy linkage
- Medical Expenditure Panel Survey (MEPS) usage and out-of-pocket burden
- Commercial and Medicaid claims from large U.S. health plans
Commercial and Medicare Part D utilization
Commercial pharmacy data and Medicare Part D reports indicate that millions of covered lives have at least one filled prescription for a GLP-1 agonist annually, with utilization concentrated in regions with higher income and more employer-sponsored or Medicare Advantage plan enrollment. Management of type 2 diabetes and, increasingly, chronic weight management without diabetes drive fills.
| Metric | Verified Detail | Source Type |
|---|---|---|
| U.S. adults reporting current GLP-1 use (NHANES) | Hundreds of thousands to single-digit millions, depending on survey window and definition | National health interview and pharmacy linkage |
| Commercial plan members with at least one GLP-1 fill (annual) | Several million covered lives | Administrative claims data from large U.S. health plans |
| Medicare Part D GLP-1 fills and beneficiaries | Multiple million prescriptions; beneficiary counts lower due to one-to-many fills | CMS plan-level data and member counts |
| Geographic concentration | Higher utilization in urban and higher-income regions | Claims and area-level survey analyses |
Who is using GLP-1 agonists and how demographics shape use
Use is more common among adults with higher household income, comprehensive insurance, and access to specialty care, reflecting both cost barriers and prescriber preferences. People using these medications are more likely to have or be at risk for type 2 diabetes, cardiovascular disease markers, or obesity. Disparities by age, race, ethnicity, and geography persist, often mirroring broader access and digital literacy challenges rather than biological differences.
Global estimates and cross-country variation
Outside the United States, national programs with tight formularies, such as NICE in the United Kingdom and PBAC/PBS in Australia, cover GLP-1 agonists for specific indications, typically type 2 diabetes and, in some regions, obesity meeting strict criteria. Primary care gatekeeping and reimbursement restrictions limit the number of people who can be treated at any time, even where guidelines support use. Data on exact prevalence are sparse; regional health system reports and published surveillance suggest use is growing but remains concentrated in higher-income countries and within urban centers where specialty care is accessible.
| Country/Region | Eligibility and reimbursement scope | Available indicators of use |
|---|---|---|
| United States | Broad private coverage for type 2 diabetes and obesity; limited Medicare coverage for weight management until policy changes | Claims fills, NHANES pharmacy linkage |
| United Kingdom (NICE) | Diabetes and obesity indications under structured commissioning pathways and specialist care requirements | Specialist registry data, NHS Digital prescribing |
| Australia (PBS) | Restricted PBS coverage for diabetes and select obesity cases with prior specialist assessment | Pharmacy claims and PBS reports |
| Canada | Provincial formularies vary; limited public coverage for weight management | Provincial drug plans and registry samples |
Barriers that limit precise counting of GLP-1 users
Several factors complicate exact measurement, including short data lags, private pharmacy cash purchases not captured in scripts, and differing definitions of current use across surveys. Payer rules can change, affecting coverage and thus measured utilization. Additionally, rapid product expansion means point-in-time estimates can quickly become outdated, especially for newer combinations and higher-dose regimens.
What reliable indicators do show and why they matter
Although an exact global headcount is not available, consistent signals from claims, surveys, and health system reports indicate rising use. Growth affects drug supply, pricing dynamics, clinical workforce needs, and requirements for monitoring and follow-up care. Reliable trend data support planning for diabetes and cardiovascular care, workforce capacity, and policies that address access inequities and ensure safe use.
Sustainability of use and access considerations
Continued expansion depends on manufacturing capacity, reimbursement policies, and evidence on long-term safety and effectiveness. Structured follow-up, adherence support, and attention to barriers by income, geography, and language can sustain appropriate use and reduce inequities. Monitoring should account for product lifecycle, guideline updates, and evolving payer criteria to ensure that growth aligns with clinical value and population health goals.